Development of Potent and Selective Antagonists for the UTP-Activated P2Y<sub>4</sub> Receptor
作者:Muhammad Rafehi、Enas M. Malik、Alexander Neumann、Aliaa Abdelrahman、Theodor Hanck、Vigneshwaran Namasivayam、Christa E. Müller、Younis Baqi
DOI:10.1021/acs.jmedchem.7b00030
日期:2017.4.13
nM, selectivity versus other P2Y receptor subtypes, and is thought to act as an allosteric antagonist. A receptor homology model was built and docking studies were performed to analyze ligand–receptor interactions. Compound 64 (PSB-1699, sodium 1-amino-4-[4-(3-pyridin-3-ylmethylthio)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate) represents the most selective P2Y4 receptor antagonist known
P2Y 4是由尿苷5'-三磷酸(UTP)激活的Gq蛋白偶联受体,在体内,例如在肠,心脏和脑中广泛表达。到目前为止,尚未描述选择性P2Y 4受体拮抗剂。因此,我们开发和优化了基于蒽醌支架的P2Y 4受体拮抗剂。通过基于荧光的测定法评估效价,该测定法测量了稳定转染了人P2Y 4受体的1321N1星形细胞瘤细胞中UTP诱导的细胞内钙释放的抑制作用。本系列中最有效的化合物,钠1-氨基-4- [4-(2,4-二甲基苯硫基)苯基氨基] -9,10-二氧代-9,10-二氢蒽-2-磺酸盐(PSB-16133,61)表现出233 nM的IC 50值,相对于其他P2Y受体亚型具有选择性,并被认为是一种变构拮抗剂。建立了受体同源性模型,并进行了对接研究以分析配体-受体的相互作用。化合物64(PSB-1699,1-氨基-4- [4-(3-吡啶-3-基甲硫基)苯基氨基] -9,10-二氧代-9,10-二氢蒽-2-磺